Emerging role of probiotics and antimicrobials in the management of irritable bowel syndrome

References

• Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130:1480-91
   PubMed Web of Science ®Google Scholar
• American College of Gastroenterology Task Force on IBS. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009;104(Suppl 1):S1-35
   Google Scholar
• Simrén M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 2013;62:159-76
   PubMed Web of Science ®Google Scholar
• Engsbro AL, Simren M, Bytzer P. Short-term stability of subtypes in the irritable bowel syndrome: prospective evaluation using the Rome III classification. Aliment Pharmacol Ther 2012;35:350-9
   PubMed Web of Science ®Google Scholar
• Saito YA, Schoenfeld P, Locke GR, III. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 2002;97:1910-15
   PubMed Web of Science ®Google Scholar
• Hungin AP, Chang L, Locke GR, et al. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther 2005;21:1365-75
   PubMed Web of Science ®Google Scholar
• Hulisz D. The burden of illness of irritable bowel syndrome: current challenges and hope for the future. J Manag Care Pharm 2004;10:299-309
   PubMedGoogle Scholar
• Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part II: lower gastrointestinal diseases. Gastroenterology 2009;136:741-54
   PubMed Web of Science ®Google Scholar
• Longstreth GF, Wilson A, Knight K, et al. Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective. Am J Gastroenterol 2003;98:600-7
   PubMed Web of Science ®Google Scholar
• Rey E, García-Alonso MO, Moreno-Ortega M, et al. Determinants of quality of life in irritable bowel syndrome. J Clin Gastroenterol 2008;42:1003-9
   PubMed Web of Science ®Google Scholar
• DiBonaventura M, Sun SX, Bolge SC, et al. Health-related quality of life, work productivity and health care resource use associated with constipation predominant irritable bowel syndrome. Curr Med Res Opin 2011;27:2213-22
   PubMed Web of Science ®Google Scholar
• Cash B, Sullivan S, Barghout V. Total costs of IBS: employer and managed care perspective. Am J Manag Care 2005;11:S7-16
   PubMed Web of Science ®Google Scholar
• Dean BB, Aguilar D, Barghout V, et al. Impairment in work productivity and health-related quality of life in patients with IBS. Am J Manag Care 2005;11:S17-26
   PubMed Web of Science ®Google Scholar
• Sachdev AH, Pimentel M. Antibiotics for irritable bowel syndrome: rationale and current evidence. Curr Gastroenterol Rep 2012;14:439-45
   PubMedGoogle Scholar
• Frissora CL, Cash BD. Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome. Aliment Pharmacol Ther 2007;25:1271-81
   PubMed Web of Science ®Google Scholar
• Walters JR, Pattni SS. Managing bile acid diarrhoea. Therap Adv Gastroenterol 2010;3:349-57
   PubMedGoogle Scholar
• FDA approves Linzess to treat certain cases of irritable bowel syndrome and constipation. 30 August 2012. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm317505.htm [Last accessed 6 August 2013]
   Google Scholar
• Wilkins T, Pepitone C, Alex B, et al. Diagnosis and management of IBS in adults. Am Fam Physician 2012;86:419-26
   PubMed Web of Science ®Google Scholar
• van Tilburg MA, Palsson OS, Levy RL, et al. Complementary and alternative medicine use and cost in functional bowel disorders: a six month prospective study in a large HMO. BMC Complement Altern Med 2008;8:46
   PubMed Web of Science ®Google Scholar
• Chey WD, Maneerattaporn M, Saad R. Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome. Gut Liver 2011;5:253-66
   PubMed Web of Science ®Google Scholar
• Luckey TD. Introduction to intestinal microecology. Am J Clin Nutr 1972;25:1292-4
   PubMed Web of Science ®Google Scholar
• Sekirov I, Russell SL, Antunes LC, et al. Gut microbiota in health and disease. Physiol Rev 2010;90:859-904
   PubMed Web of Science ®Google Scholar
• Frank DN, St Amand AL, Feldman RA, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 2007;104:13780-5
   PubMed Web of Science ®Google Scholar
• Ghoshal UC, Shukla R, Ghoshal U, et al. The gut microbiota and irritable bowel syndrome: friend or foe? Int J Inflam 2012;2012:151085
   PubMedGoogle Scholar
• Clarke G, Cryan JF, Dinan TG, et al. Review article: probiotics for the treatment of irritable bowel syndrome – focus on lactic acid bacteria. Aliment Pharmacol Ther 2012;35:403-13
   PubMed Web of Science ®Google Scholar
• Spahn TW, Kucharzik T. Modulating the intestinal immune system: the role of lymphotoxin and GALT organs. Gut 2004;53:456-65
   PubMed Web of Science ®Google Scholar
• Faith JJ, Guruge JL, Charbonneau M, et al. The long-term stability of the human gut microbiota. Science 2013;341:1237439
   PubMed Web of Science ®Google Scholar
• Quigley EM, Craig OF. Irritable bowel syndrome; update on pathophysiology and management. Turk J Gastroenterol 2012;23:313-22
   PubMed Web of Science ®Google Scholar
• Pimentel M, Lin HC, Enayati P, et al. Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. Am J Physiol Gastrointest Liver Physiol 2006;290:G1089-95
   PubMed Web of Science ®Google Scholar
• Collins SM, Bercik P. The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology 2009;136:2003-14
   PubMed Web of Science ®Google Scholar
• Ford AC, Spiegel BM, Talley NJ, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2009;7:1279-86
   PubMed Web of Science ®Google Scholar
• Quigley EM. Small intestinal bacterial overgrowth: what it is and what it is not. Curr Opin Gastroenterol 2014;30:141-6
   PubMed Web of Science ®Google Scholar
• Halvorson HA, Schlett CD, Riddle MS. Postinfectious irritable bowel syndrome – a meta-analysis. Am J Gastroenterol 2006;101:1894-9
   PubMed Web of Science ®Google Scholar
• Thabane M, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2007;26:535-44
   PubMed Web of Science ®Google Scholar
• Neal KR, Barker L, Spiller RC. Prognosis in post-infective irritable bowel syndrome: a six year follow up study. Gut 2002;51:410-13
   PubMed Web of Science ®Google Scholar
• Smith JL, Bayles D. Postinfectious irritable bowel syndrome: a long-term consequence of bacterial gastroenteritis. J Food Prot 2007;70:1762-9
   PubMed Web of Science ®Google Scholar
• Porter CK, Choi D, Cash B, et al. Pathogen-specific risk of chronic gastrointestinal disorders following bacterial causes of foodborne illness. BMC Gastroenterol 2013;13:46
   PubMed Web of Science ®Google Scholar
• Lee BJ, Bak YT. Irritable bowel syndrome, gut microbiota and probiotics. J Neurogastroenterol Motil 2011;17:252-66
   PubMed Web of Science ®Google Scholar
• Verna EC, Lucak S. Use of probiotics in gastrointestinal disorders: what to recommend? Therap Adv Gastroenterol 2010;3:307-19
   PubMedGoogle Scholar
• Ohland CL, MacNaughton WK. Probiotic bacteria and intestinal epithelial barrier function. Am J Physiol Gastrointest Liver Physiol 2010;298:G807-19
   PubMed Web of Science ®Google Scholar
• Ewaschuk JB, Diaz H, Meddings L, et al. Secreted bioactive factors from Bifidobacterium infantis enhance epithelial cell barrier function. Am J Physiol Gastrointest Liver Physiol 2008;295:G1025-34
   PubMed Web of Science ®Google Scholar
• Rousseaux C, Thuru X, Gelot A, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 2007;13:35-7
   PubMed Web of Science ®Google Scholar
• Ortiz-Lucas M, Tobias A, Saz P, et al. Effect of probiotic species on irritable bowel syndrome symptoms: a bring up to date meta-analysis. Rev Esp Enferm Dig 2013;105:19-36
   PubMed Web of Science ®Google Scholar
• Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS One 2012;7:e34938
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010;59:325-32
   PubMed Web of Science ®Google Scholar
• Kim HJ, Camilleri H, McKinzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003;17:895-904
   PubMed Web of Science ®Google Scholar
• Tsuchiya J, Barreto R, Okura R, et al. Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin J Dig Dis 2004;5:169-74
   PubMedGoogle Scholar
• Kajander K, Hatakka K, Poussa T, et al. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 2005;22:387-94
   PubMed Web of Science ®Google Scholar
• Drouault-Holowacz S, Bieuvelet S, Burckel A, et al. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroenterol Clin Biol 2008;32:147-52
   PubMedGoogle Scholar
• Nobaek S, Johansson ML, Molin G, et al. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000;95:1231-8
   PubMed Web of Science ®Google Scholar
• Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001;13:1143-7
   PubMed Web of Science ®Google Scholar
• Sinn DH, Song JH, Kim HJ, et al. Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci 2008;53:2714-8
   PubMed Web of Science ®Google Scholar
• Long ZR, Yu CH, Yang Y, et al. [Clinical observation on acupuncture combined with microorganism pharmaceutical preparations for treatment of irritable bowel syndrome of constipation type]. Zhongguo Zhen Jiu 2006;26:403-5
   PubMedGoogle Scholar
• Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006;101:1581-90
   PubMed Web of Science ®Google Scholar
• Gade J, Thorn P. Paraghurt for patients with irritable bowel syndrome. A controlled clinical investigation from general practice. Scand J Prim Health Care 1989;7:23-6
   PubMedGoogle Scholar
• Yang YX, He M, Hu G, et al. Effect of a fermented milk containing Bifidobacterium lactis DN-173010 on Chinese constipated women. World J Gastroenterol 2008;14:6237-43
   PubMed Web of Science ®Google Scholar
• Koebnick C, Wagner I, Leitzmann P, et al. Probiotic beverage containing Lactobacillus casei Shirota improves gastrointestinal symptoms in patients with chronic constipation. Can J Gastroenterol 2003;17:655-9
   PubMed Web of Science ®Google Scholar
• Jayasimhan S, Yap NY, Roest Y, et al. Efficacy of microbial cell preparation in improving chronic constipation: a randomized, double-blind, placebo-controlled trial. Clin Nutr 2013;32:928–34
   PubMed Web of Science ®Google Scholar
• Mazlyn MM, Nagarajah LH, Fatimah A, et al. Effects of a probiotic fermented milk on functional constipation: a randomized, double-blind, placebo-controlled study. J Gastroenterol Hepatol 2013;28:1141-7
   PubMed Web of Science ®Google Scholar
• Riezzo G, Orlando A, D’Attoma B, et al. Randomised clinical trial: efficacy of Lactobacillus paracasei-enriched artichokes in the treatment of patients with functional constipation – a double-blind, controlled, crossover study. Aliment Pharmacol Ther 2012;35:441-50
   PubMed Web of Science ®Google Scholar
• Fateh R, Iravani S, Frootan M, et al. Symbiotic preparation in men suffering from functional constipation: a randomised controlled trial. Swiss Med Wkly 2011;141:w13239
   PubMed Web of Science ®Google Scholar
• De Paula JA, Carmuega E, Weill R. Effect of the ingestion of a symbiotic yogurt on the bowel habits of women with functional constipation. Acta Gastroenterol Latinoam 2008;38:16-25
   PubMedGoogle Scholar
• Ringel-Kulka T, Palsson OS, Maier D, et al. Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study. J Clin Gastroenterol 2011;45:518-25
   PubMed Web of Science ®Google Scholar
• Rogers NJ, Mousa SA. The shortcomings of clinical trials assessing the efficacy of probiotics in irritable bowel syndrome. J Altern Complement Med 2012;18:112-19
   PubMed Web of Science ®Google Scholar
• Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;364:22-32
   PubMed Web of Science ®Google Scholar
• Tack J. Antibiotic therapy for the irritable bowel syndrome. N Engl J Med 2011;364:81-2
   PubMed Web of Science ®Google Scholar
• Basseri RJ, Weitsman S, Barlow GM, et al. Antibiotics for the treatment of irritable bowel syndrome. Gastroenterol Hepatol (NY) 2011;7:455-93
   PubMedGoogle Scholar
• Nayak AK, Karnad DR, Abraham P, et al. Metronidazole relieves symptoms in irritable bowel syndrome: the confusion with so-called ‘chronic amebiasis’. Indian J Gastroenterol 1997;16:137-9
   PubMedGoogle Scholar
• Dear KL, Elia M, Hunter JO. Do interventions which reduce colonic bacterial fermentation improve symptoms of irritable bowel syndrome? Dig Dis Sci 2005;50:758-66
   PubMed Web of Science ®Google Scholar
• Engsbro AL, Stensvold CR, Nielsen HV, et al. Treatment of Dientamoeba fragilis in patients with irritable bowel syndrome. Am J Trop Med Hyg 2012;87:1046-52
   PubMed Web of Science ®Google Scholar
• Blondeau JM. What have we learned about antimicrobial use and the risks for Clostridium difficile-associated diarrhoea? J Antimicrob Chemother 2009;63:238-42
   PubMed Web of Science ®Google Scholar
• Neomycin Sulfate Tablets USP [package insert]. Sellersville, PA: Teva Pharmaceuticals, USA, 2007
   Google Scholar
• Pimentel M, Chatterjee S, Chow EJ, et al. Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study. Dig Dis Sci 2006;51:1297-301
   PubMed Web of Science ®Google Scholar
• Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003;98:412-19
   PubMed Web of Science ®Google Scholar
• Ward KM, Rounthwaite FJ. Neomycin ototoxicity. Ann Otol Rhinol Laryngol 1978;87:211-15
   PubMed Web of Science ®Google Scholar
• Yang J, Lee HR, Low K, et al. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. Dig Dis Sci 2008;53:169-74
   PubMed Web of Science ®Google Scholar
• Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 2005;51(Suppl 1):36-66
   PubMed Web of Science ®Google Scholar
• Koo HL, DuPont HL. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol 2010;26:17-25
   PubMed Web of Science ®Google Scholar
• Xifaxan (rifaximin) tablets [package insert]. Raleigh, NC: Salix Pharmaceuticals Inc., 2012
   Google Scholar
• Menees SB, Maneerattannaporn M, Kim HM, et al. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 2012;107:28-35
   PubMed Web of Science ®Google Scholar
• Sharara AI, Aoun E, Abdul-Baki H, et al. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006;101:326-33
   PubMed Web of Science ®Google Scholar
• Jolley J. High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome. Clin Exp Gastroenterol 2011;4:43-8
   PubMedGoogle Scholar
• Di Stefano M, Tana P, Mengoli C, et al. Colonic hypersensitivity is a major determinant of the efficacy of bloating treatment in constipation-predominant irritable bowel syndrome. Intern Emerg Med 2011;6:403-11
   PubMed Web of Science ®Google Scholar
• Meyrat P, Safroneeva E, Schoepfer AM. Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months. Aliment Pharmacol Ther 2012;36:1084-93
   PubMed Web of Science ®Google Scholar
• Scarpellini E, Giorgio V, Gabrielli M, et al. Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome. Eur Rev Med Pharmacol Sci 2013;17:1314-20
   PubMed Web of Science ®Google Scholar
• Low K, Hwang L, Hua J, et al. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. J Clin Gastroenterol 2010;44:547-50
   PubMed Web of Science ®Google Scholar
• Farrell DJ. Rifaximin in the treatment of irritable bowel syndrome: is there a high risk for development of antimicrobial resistance? J Clin Gastroenterol 2013;47:205-11
   PubMed Web of Science ®Google Scholar
• Debbia EA, Maioli E, Roveta S, et al. Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations. J Chemother 2008;20:186-94
   PubMed Web of Science ®Google Scholar
• Pimentel M, Morales W, Chua K, et al. Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects. Dig Dis Sci 2011;56:2067-72
   PubMed Web of Science ®Google Scholar